Antiviral Action of FetTech’s Multi-Tissue Platform (MTP) Powder and Gel
Scroll below for the full whitepaper >
Enveloped viruses, or viruses with lipid bilayer membranes on the outer part of the virus, are responsible for some of the most common infections known to mankind. while infections resulting from enveloped viruses are typically less severe than non-enveloped relatives, enveloped viruses are responsible for some of the deadliest epidemics and pandemics in human history. Enveloped viruses include the viral families Herpesviridae, filovirus, retroviruses, Hepatitis Delta Virus, Flaviviridae, Influenza Viruses, and Coronavirus which cause Herpes, Ebola, Human Immunodeficiency Virus (HIV), Hepatitis D, West Nile, Zika, Influenza, and COVID-19. Enveloped viruses are also more likely to cause zoonotic infections1, creating additional risk for unknown pathogens to emerge and threaten human health.
While significant research and innovation have been dedicated towards identifying treatments and vaccines against these viruses, there is a need for broad spectrum antiviral agents that can mitigate their infectivity. Many new therapies are often specific for single strains and may be obviated within months to years should the strain evolve. Conversely, broad spectrum antivirals may target numerous pathogens but with relatively low efficacy.
Finally, new viral strains are constantly emerging, indicating the need for proactive threat-agnostic interventions. FetTech has discovered their Multi-Tissue Platform (MTP) products contain potent intrinsic antiviral properties and are developing the MTP as a threat-agnostic antiviral agent. The MTP represents a novel departure from canonical antiviral approaches (vaccines and pharmaceuticals) – Comprised of extracellular matrices (ECMs) derived from multiple tissue types (e.g., lung and spleen), the MTP is an acellular material originally developed for wound healing that includes cell-derived trophic factors (e.g. FGF, VEGF, EGF), hyaluronic acid, forms of collagen, fibronectin, and proteoglycans. The MTP works by supporting structural integrity and bioactivity to supplement tissue loss/damage. It acts locally to provide basic building blocks for the body to regenerate tissue following insult. Following application, the MTP facilitates the recruitment of stem cells to the implant site, modulating the body’s inflammatory response to that of a regenerative response, and inducing angiogenesis. Originally developed and currently FDA 510(k) cleared in both powder and gel formulations as a treatment for trauma wounds and burns, our MTP is a shelf stable material distributable in harsh climates without expensive supply chain considerations that innately promotes wound healing through increased angiogenesis and immune cell activation, all while inactivating enveloped viral entities within one hour of exposure.